BACKGROUND: Measurements of plasma normetanephrine (NMN) and metanephrine (MN) provide a sensitive test for diagnosis of phaeochromocytomas and paragangliomas (PPGLs), but do not allow detection of dopamine-producing tumours. Here we introduce a novel mass spectrometric based method coupled to ultraperformance liquid chromatography (LC-MS/MS) for measuring NMN, MN and 3-methoxytyramine (MTY), the O-methylated metabolite of dopamine. METHODS: Specific collision-induced fragment ions assessed by multireaction monitoring transitions were used for identification, with quantification according to signal intensities of analytes relative to stable isotope labelled internal standards. Results for solid-phase extracted samples from 196 subjects analysed by LC-MS/MS were compared with those analysed by liquid chromatography with electrochemical detection (LC-ECD). Concentration ranges in 125 volunteers were compared with those from 63 patients with PPGLs, including 14 with metastatic disease. RESULTS: The LC-MS/MS method showed linearity over four orders of magnitude with analytical sensitivity sufficient to measure to 0.02 nmol/L. Intra- and inter-assay coefficients of variation ranged from 2.8% to 13.5%. NMN and MN were respectively measured 17% and 10% higher and MTY 26% lower by LC-MS/MS than by LC-ECD. Medians and ranges for 3-methoxytramine, NMN and MN were respectively 0.08 (0.03-0.13), 0.35 (0.13-0.95) and 0.15 (0.07-0.33) nmol/L in volunteers. Among patients with PPGLs, plasma methoxytyramine was six-fold higher in patients with than without metastastases (1.09 versus 0.19 nmol/L) and in three patients was the only metabolite increased. CONCLUSIONS: The LC-MS/MS method enables accurate, selective and sensitive measurements of catecholamine O-methylated metabolites that should be particularly useful for screening and management of dopamine-producing metastatic PPGLs.
BACKGROUND: Measurements of plasma normetanephrine (NMN) and metanephrine (MN) provide a sensitive test for diagnosis of phaeochromocytomas and paragangliomas (PPGLs), but do not allow detection of dopamine-producing tumours. Here we introduce a novel mass spectrometric based method coupled to ultraperformance liquid chromatography (LC-MS/MS) for measuring NMN, MN and 3-methoxytyramine (MTY), the O-methylated metabolite of dopamine. METHODS: Specific collision-induced fragment ions assessed by multireaction monitoring transitions were used for identification, with quantification according to signal intensities of analytes relative to stable isotope labelled internal standards. Results for solid-phase extracted samples from 196 subjects analysed by LC-MS/MS were compared with those analysed by liquid chromatography with electrochemical detection (LC-ECD). Concentration ranges in 125 volunteers were compared with those from 63 patients with PPGLs, including 14 with metastatic disease. RESULTS: The LC-MS/MS method showed linearity over four orders of magnitude with analytical sensitivity sufficient to measure to 0.02 nmol/L. Intra- and inter-assay coefficients of variation ranged from 2.8% to 13.5%. NMN and MN were respectively measured 17% and 10% higher and MTY 26% lower by LC-MS/MS than by LC-ECD. Medians and ranges for 3-methoxytramine, NMN and MN were respectively 0.08 (0.03-0.13), 0.35 (0.13-0.95) and 0.15 (0.07-0.33) nmol/L in volunteers. Among patients with PPGLs, plasma methoxytyramine was six-fold higher in patients with than without metastastases (1.09 versus 0.19 nmol/L) and in three patients was the only metabolite increased. CONCLUSIONS: The LC-MS/MS method enables accurate, selective and sensitive measurements of catecholamine O-methylated metabolites that should be particularly useful for screening and management of dopamine-producing metastatic PPGLs.
Authors: David Taïeb; Alexandre Kaliski; Carsten C Boedeker; Victoria Martucci; Tito Fojo; John R Adler; Karel Pacak Journal: Endocr Rev Date: 2014-07-17 Impact factor: 19.871
Authors: Elise M Blanchet; David Taieb; Corina Millo; Victoria Martucci; Clara C Chen; Maria Merino; Peter Herscovitch; Karel Pacak Journal: J Nucl Med Date: 2015-09-10 Impact factor: 10.057
Authors: M Reimann; N Qin; M Gruber; S R Bornstein; C Kirschbaum; T Ziemssen; G Eisenhofer Journal: Int J Obes (Lond) Date: 2017-02-06 Impact factor: 5.095
Authors: Michaela Kuhlen; Christina Pamporaki; Marina Kunstreich; Stefan A Wudy; Michaela F Hartmann; Mirko Peitzsch; Christian Vokuhl; Guido Seitz; Michael C Kreissl; Thorsten Simon; Barbara Hero; Michael C Frühwald; Peter Vorwerk; Antje Redlich Journal: Front Endocrinol (Lausanne) Date: 2022-06-17 Impact factor: 6.055
Authors: Susan Richter; Mirko Peitzsch; Elena Rapizzi; Jacques W Lenders; Nan Qin; Aguirre A de Cubas; Francesca Schiavi; Jyotsna U Rao; Felix Beuschlein; Marcus Quinkler; Henri J Timmers; Giuseppe Opocher; Massimo Mannelli; Karel Pacak; Mercedes Robledo; Graeme Eisenhofer Journal: J Clin Endocrinol Metab Date: 2014-07-11 Impact factor: 5.958
Authors: Christina Pamporaki; Barbora Hamplova; Mirko Peitzsch; Aleksander Prejbisz; Felix Beuschlein; Henri J L M Timmers; Martin Fassnacht; Barbara Klink; Maya Lodish; Constantine A Stratakis; Angela Huebner; Stephanie Fliedner; Mercedes Robledo; Richard O Sinnott; Andrzej Januszewicz; Karel Pacak; Graeme Eisenhofer Journal: J Clin Endocrinol Metab Date: 2017-04-01 Impact factor: 5.958
Authors: Yaxin An; Manja Reimann; Jimmy Masjkur; Katharina Langton; Mirko Peitzsch; Timo Deutschbein; Martin Fassnacht; Natalie Rogowski-Lehmann; Felix Beuschlein; Stephanie Fliedner; Anthony Stell; Aleksander Prejbisz; Andrzej Januszewicz; Jacques Lenders; Stefan R Bornstein; Graeme Eisenhofer Journal: Int J Obes (Lond) Date: 2018-03-03 Impact factor: 5.095
Authors: M Araujo-Castro; E Pascual-Corrales; L Nattero Chavez; A Martínez Lorca; T Alonso-Gordoa; J Molina-Cerrillo; J Lorca Álvaro; C Mínguez Ojeda; S Redondo López; R Barberá Durbán; R Polo López; N Moreno Mata; U Caballero Silva; H Pian; I Ruz-Caracuel; A Sanjuanbenito Dehesa; V Gómez Dos Santos; A B Serrano Romero Journal: J Endocrinol Invest Date: 2021-07-25 Impact factor: 4.256